http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0315553-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bf8ddd7435c69cd1b353b1292981d68 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593 |
| filingDate | 2003-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c97227fb1d619aa5464a38becbddd13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b767039829e76a592fefdc9afe7656a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38a7e7f5ac04e43a690316919876f4ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0d9b833f24a11c14e576f1f3d27dd92 |
| publicationDate | 2005-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0315553-A |
| titleOfInvention | Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, method of treatment or prophylaxis of secondary hyperparathyroidism, and use of a compound, optionally in conjunction with another therapeutically active compound |
| abstract | "COMPOSITION, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PROPHYLAXY OF DISEASES, METHOD OF TREATMENT OR PROPHYLAXIS OF SECONDARY HYPERPARATIREOIDISM, AND, USE OF A COMPOUND, OPTIONALLY AS A COMPOSITION TO THE OTHER. Compounds according to formula I: wherein in said formula R1 and R2, which may be the same or different, represent halogen, (C 1 -C 6) hydrocarbyl, optionally substituted with one or two hydroxyl groups in one or more fluorine atoms, or together with the carbon atom to which they are both attached, R 1 and R 2 form a (C 3 -C 6) carbocyclic ring, or one of R 1 and R 2, considered at R 3 together forms a direct bond to form a triple bond, or R 1 and R 2 both represent hydrogen; R 3, when not forming a direct bond with one of R 1 and R 2, represents hydrogen or (C 1-1 -C 3) hydrocarbyl; X represents (E) -ethylene, (Z) -ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; the bond between C <sym> 16 and C <sym> 17 is illustrated with a dotted line to illustrate that said bond may be a single bond, in which case the projection of ring substituents is beta, or may be a double Link; A represents hydroxyl, fluorine or hydrogen; B represents CH ~ 2 ~ or H ~ 2 ~; the setting is position 3 corresponding to the same setting as natural vitamin D 3; (normal), or the setting in the 3 position setting is opposite to that of natural vitamin D ~ 3 ~ (epi); provided that when X represents (E) -ethylene or (Z) -ethylene, one of R 1 and R 2 taken together with R 3 may not form a direct bond such that a triple bond is formed. , provided that, when X represents a bond, R1 and R2 are not hydrogen; provided that the compound of formula I is not 3 (S) -hydroxy-9,10-secocholesta5 (Z), 7 (E), 10 (19), 22 (E), 24-penta-ene and prodrugs and their stereoisomeric forms are provided in conjunction with their use in therapy and their use in the manufacture of medicaments. |
| priorityDate | 2002-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.